Cognitive impairment in schizophrenia

Richard S E Keefe, Philip D Harvey

Research output: Chapter in Book/Report/Conference proceedingChapter

235 Citations (Scopus)

Abstract

Cognitive functioning is moderately to severely impaired in patients with schizophrenia. This impairment is the prime driver of the significant disabilities in occupational, social, and economic functioning in patients with schizophrenia and an important treatment target. The profile of deficits in schizophrenia includes many of the most important aspects of human cognition: attention, memory, reasoning, and processing speed. While various efforts are under way to identify specific aspects of neurocognition that may lie closest to the neurobiological etiology and pathophysiology of the illness, and may provide relevant convergence with animal models of cognition, standard neuropsychological measures continue to demonstrate the greatest sensitivity to functionally relevant cognitive impairment. The effects of antipsychotic medications on cognition in schizophrenia and first-episode psychosis appear to be minimal. Important work on the effects of add-on pharmacologic treatments is ongoing. Very few of the studies completed to date have had sufficient statistical power to generate firm conclusions; recent studies examining novel add-on treatments have produced some encouraging findings. Cognitive remediation programs have generated considerable interest as these methods are far less costly than pharmacologic treatment and are likely to be safer. A growing consensus suggests that these interventions produce modest gains for patients with schizophrenia, but the efficacy of the various methods used has not been empirically investigated.

Original languageEnglish
Title of host publicationHandbook of Experimental Pharmacology
Pages11-37
Number of pages27
Volume213
DOIs
StatePublished - Nov 8 2012

Publication series

NameHandbook of Experimental Pharmacology
Volume213
ISSN (Print)01712004
ISSN (Electronic)18650325

Fingerprint

Remediation
Antipsychotic Agents
Schizophrenia
Animals
Data storage equipment
Economics
Cognition
Processing
Therapeutics
Psychotic Disorders
Consensus
Animal Models
Cognitive Dysfunction

Keywords

  • Attention
  • Cognition
  • Cognitive neuroscience
  • Cognitive remediation
  • Enhancement
  • Executive functioning
  • Memory
  • Neurocognition
  • Neuropsychology
  • Processing speed
  • Social cognition

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Biochemistry

Cite this

Keefe, R. S. E., & Harvey, P. D. (2012). Cognitive impairment in schizophrenia. In Handbook of Experimental Pharmacology (Vol. 213, pp. 11-37). (Handbook of Experimental Pharmacology; Vol. 213). https://doi.org/10.1007/978-3-642-25758-2_2

Cognitive impairment in schizophrenia. / Keefe, Richard S E; Harvey, Philip D.

Handbook of Experimental Pharmacology. Vol. 213 2012. p. 11-37 (Handbook of Experimental Pharmacology; Vol. 213).

Research output: Chapter in Book/Report/Conference proceedingChapter

Keefe, RSE & Harvey, PD 2012, Cognitive impairment in schizophrenia. in Handbook of Experimental Pharmacology. vol. 213, Handbook of Experimental Pharmacology, vol. 213, pp. 11-37. https://doi.org/10.1007/978-3-642-25758-2_2
Keefe RSE, Harvey PD. Cognitive impairment in schizophrenia. In Handbook of Experimental Pharmacology. Vol. 213. 2012. p. 11-37. (Handbook of Experimental Pharmacology). https://doi.org/10.1007/978-3-642-25758-2_2
Keefe, Richard S E ; Harvey, Philip D. / Cognitive impairment in schizophrenia. Handbook of Experimental Pharmacology. Vol. 213 2012. pp. 11-37 (Handbook of Experimental Pharmacology).
@inbook{455c42bff39142e798576014b8165927,
title = "Cognitive impairment in schizophrenia",
abstract = "Cognitive functioning is moderately to severely impaired in patients with schizophrenia. This impairment is the prime driver of the significant disabilities in occupational, social, and economic functioning in patients with schizophrenia and an important treatment target. The profile of deficits in schizophrenia includes many of the most important aspects of human cognition: attention, memory, reasoning, and processing speed. While various efforts are under way to identify specific aspects of neurocognition that may lie closest to the neurobiological etiology and pathophysiology of the illness, and may provide relevant convergence with animal models of cognition, standard neuropsychological measures continue to demonstrate the greatest sensitivity to functionally relevant cognitive impairment. The effects of antipsychotic medications on cognition in schizophrenia and first-episode psychosis appear to be minimal. Important work on the effects of add-on pharmacologic treatments is ongoing. Very few of the studies completed to date have had sufficient statistical power to generate firm conclusions; recent studies examining novel add-on treatments have produced some encouraging findings. Cognitive remediation programs have generated considerable interest as these methods are far less costly than pharmacologic treatment and are likely to be safer. A growing consensus suggests that these interventions produce modest gains for patients with schizophrenia, but the efficacy of the various methods used has not been empirically investigated.",
keywords = "Attention, Cognition, Cognitive neuroscience, Cognitive remediation, Enhancement, Executive functioning, Memory, Neurocognition, Neuropsychology, Processing speed, Social cognition",
author = "Keefe, {Richard S E} and Harvey, {Philip D}",
year = "2012",
month = "11",
day = "8",
doi = "10.1007/978-3-642-25758-2_2",
language = "English",
isbn = "9783642257575",
volume = "213",
series = "Handbook of Experimental Pharmacology",
pages = "11--37",
booktitle = "Handbook of Experimental Pharmacology",

}

TY - CHAP

T1 - Cognitive impairment in schizophrenia

AU - Keefe, Richard S E

AU - Harvey, Philip D

PY - 2012/11/8

Y1 - 2012/11/8

N2 - Cognitive functioning is moderately to severely impaired in patients with schizophrenia. This impairment is the prime driver of the significant disabilities in occupational, social, and economic functioning in patients with schizophrenia and an important treatment target. The profile of deficits in schizophrenia includes many of the most important aspects of human cognition: attention, memory, reasoning, and processing speed. While various efforts are under way to identify specific aspects of neurocognition that may lie closest to the neurobiological etiology and pathophysiology of the illness, and may provide relevant convergence with animal models of cognition, standard neuropsychological measures continue to demonstrate the greatest sensitivity to functionally relevant cognitive impairment. The effects of antipsychotic medications on cognition in schizophrenia and first-episode psychosis appear to be minimal. Important work on the effects of add-on pharmacologic treatments is ongoing. Very few of the studies completed to date have had sufficient statistical power to generate firm conclusions; recent studies examining novel add-on treatments have produced some encouraging findings. Cognitive remediation programs have generated considerable interest as these methods are far less costly than pharmacologic treatment and are likely to be safer. A growing consensus suggests that these interventions produce modest gains for patients with schizophrenia, but the efficacy of the various methods used has not been empirically investigated.

AB - Cognitive functioning is moderately to severely impaired in patients with schizophrenia. This impairment is the prime driver of the significant disabilities in occupational, social, and economic functioning in patients with schizophrenia and an important treatment target. The profile of deficits in schizophrenia includes many of the most important aspects of human cognition: attention, memory, reasoning, and processing speed. While various efforts are under way to identify specific aspects of neurocognition that may lie closest to the neurobiological etiology and pathophysiology of the illness, and may provide relevant convergence with animal models of cognition, standard neuropsychological measures continue to demonstrate the greatest sensitivity to functionally relevant cognitive impairment. The effects of antipsychotic medications on cognition in schizophrenia and first-episode psychosis appear to be minimal. Important work on the effects of add-on pharmacologic treatments is ongoing. Very few of the studies completed to date have had sufficient statistical power to generate firm conclusions; recent studies examining novel add-on treatments have produced some encouraging findings. Cognitive remediation programs have generated considerable interest as these methods are far less costly than pharmacologic treatment and are likely to be safer. A growing consensus suggests that these interventions produce modest gains for patients with schizophrenia, but the efficacy of the various methods used has not been empirically investigated.

KW - Attention

KW - Cognition

KW - Cognitive neuroscience

KW - Cognitive remediation

KW - Enhancement

KW - Executive functioning

KW - Memory

KW - Neurocognition

KW - Neuropsychology

KW - Processing speed

KW - Social cognition

UR - http://www.scopus.com/inward/record.url?scp=84868328942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868328942&partnerID=8YFLogxK

U2 - 10.1007/978-3-642-25758-2_2

DO - 10.1007/978-3-642-25758-2_2

M3 - Chapter

C2 - 23027411

AN - SCOPUS:84868328942

SN - 9783642257575

VL - 213

T3 - Handbook of Experimental Pharmacology

SP - 11

EP - 37

BT - Handbook of Experimental Pharmacology

ER -